Targeting Galectin-9 to reduce HIV persistence
Modulation of Galectin-9 to Target HIV Persistence
['FUNDING_R01'] · VITALANT · NIH-11022900
This study is looking at how a protein called Galectin-9 might help HIV hide in the body even when people are on treatment, and it hopes to find new ways to get rid of the virus for good, so patients with HIV can have healthier immune systems.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VITALANT (nih funded) |
| Locations | 1 site (SCOTTSDALE, UNITED STATES) |
| Trial ID | NIH-11022900 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Galectin-9 in the persistence of HIV in patients undergoing antiretroviral therapy. It aims to understand how Galectin-9 affects immune responses and contributes to the maintenance of latent HIV in CD4+ T cells. By exploring the potential of inhibiting Galectin-9 signaling, the study seeks to develop new strategies for eradicating or functionally curing HIV infection. Patients may be involved in trials assessing the effects of this modulation on HIV persistence and immune health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy but still have detectable levels of HIV in their system.
Not a fit: Patients who are not living with HIV or those who have achieved complete viral suppression without any latent infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help eliminate HIV from the body or improve immune function in HIV-infected individuals.
How similar studies have performed: Previous research has shown promising results in targeting immune modulators like Galectin-9 for HIV treatment, indicating potential for success in this approach.
Where this research is happening
SCOTTSDALE, UNITED STATES
- VITALANT — SCOTTSDALE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PILLAI, SATISH KUMAR — VITALANT
- Study coordinator: PILLAI, SATISH KUMAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus